You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME/CE

Guidelines Address Screening for Nonviral STIs in Teens

  • Authors: News Author: Larry Hand
    CME Author: Laurie Barclay, MD
  • CME/CE Released: 9/9/2014
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/9/2015, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This article is intended for primary care clinicians, infectious disease specialists, adolescent medicine specialists, nurses, and other clinicians who are in a position to screen for sexually transmitted infections in adolescents.

The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Describe American Academy of Pediatrics recommendations for screening for specific nonviral sexually transmitted infections among adolescents.
  2. Describe the role of the clinician in reducing the prevalence and adverse sequelae of sexually transmitted infections.


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author

  • Larry Hand

    Freelance writer, Medscape

    Disclosures

    Disclosure: Larry Hand has disclosed no relevant financial relationships.

Editor

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer, Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Medscape, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME/CE

Guidelines Address Screening for Nonviral STIs in Teens

Authors: News Author: Larry Hand CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME/CE Released: 9/9/2014

Valid for credit through: 9/9/2015, 11:59 PM EST

processing....

Clinical Context

Adolescents have the highest prevalence rates for many sexually transmitted infections (STIs). Early detection of nonviral STIs facilitates treatment, prevents transmission, and avoids complications.

Chlamydia, gonorrhea, and syphilis screening guidelines from the US Preventive Services Task Force and the Centers for Disease Control and Prevention recommend screening those at risk based on epidemiologic and clinical outcomes data. This American Academy of Pediatrics (AAP) policy statement regarding these curable, nonviral STIs summarizes the evidence for nonviral STI screening in adolescents, discusses the value of screening, and offers recommendations for routine screening of adolescents for nonviral STIs.

Study Synopsis and Perspective

The AAP has recommended routine laboratory screening for nonviral STIs in some adolescents and young adults in a policy statement published online June 30 in Pediatrics.

The AAP's Committee on Adolescence and Society for Adolescent Health and Medicine developed the policy statement and recommendations "to identify and treat individuals with treatable infections, reduce transmission to others, avoid or minimize long-term consequences, identify other exposed and potentially infected individuals, and decrease the prevalence of infection in a community."

Although prevalence rates of some STIs are highest among adolescents, nonviral STIs can be treated and transmission to others eliminated if they are caught early, the authors write. The US Preventive Services Task Force and the Centers for Disease Control and Prevention have published similar guidelines.

The AAP recommendations cover chlamydia, gonorrhea, trichomoniasis, and syphilis.

Specifically, the academy recommends routine laboratory screening for chlamydia:

  • in all sexually active female adolescents and young adults (<25 years) annually;
  • in sexually active adolescent and young adult men who have sex with other men (MSM) at least annually, and every 3 to 6 months if at high risk;
  • in adolescents and young adults exposed to chlamydia in the past 60 days; and
  • possibly in sexually active young men annually who are in high-prevalence environments, such as jails or detention centers; national job training programs; and STI clinics, high school clinics, or adolescent clinics for patients with a history of multiple sex partners.

The academy recommends routine laboratory screening for gonorrhea:

  • in sexually active female adolescents and young adults annually;
  • in sexually active adolescent and young adult MSM annually, and every 3 to 6 months if high risk (those who have multiple or anonymous sex partners, sex combined with illicit drug use, or partners who engage in these activities);
  • in adolescents and young adults exposed to gonorrhea from an infected partner in the past 60 days; and
  • possibly in sexually active adolescent and young adult men with individual or population-based risk factors.

The academy recommends against routine screening of asymptomatic adolescents for trichomoniasis but suggests that this screening may be necessary for female adolescents and young adults who have new or multiple partners, have a history of STIs, exchange sex for money, or inject drugs.

The academy recommends against routine screening for syphilis in nonpregnant, heterosexual adolescents but recommends screening for all sexually active adolescent and young adult MSM annually or every 3 to 6 months if at high risk. It also recommends the following:

  • Rescreen all adolescents infected with chlamydia or gonorrhea, and consider rescreening all female adolescents and young adults diagnosed with trichomoniasis, 3 months after treatment.
  • Develop clinical procedures to incorporate risk assessments, screening, treatment, and prevention counseling into routine healthcare.
  • Work to minimize barriers to screening and other barriers such as access and stigma.

"Pediatricians can take an active role in reducing disease prevalence and adverse sequelae by identifying and treating undiagnosed infections," the authors write.

Pediatrics. Published online June 30, 2014. Abstract

Guideline Highlights

  • All sexually active female adolescents and adults 25 years or younger should be routinely screened annually for Chlamydia trachomatis and Neisseria gonorrheae.
  • Sexually active adolescent and young adult MSM should be routinely screened annually for rectal and urethral chlamydia and gonorrhea if they participate in receptive anal or insertive intercourse, respectively.
  • MSM participating in receptive oral sex should also be routinely screened annually for pharyngeal gonorrhea.
  • High-risk patients (multiple or anonymous partners, sex combined with illicit drug use, or partners who participate in these activities) should be screened every 3 to 6 months for chlamydia and gonorrhea.
  • Adolescents and young adults exposed in the past 60 days to chlamydia or gonorrhea from an infected partner should be screened for these respective infections.
  • Annual screening for chlamydia or gonorrhea should be considered for sexually active young men in high-prevalence settings, such as jails or juvenile corrections facilities, national job training programs, STI clinics, high school clinics, and adolescent clinics for patients who have a history of multiple partners.
  • Regardless of whether they believe that their sex partners were treated, all adolescents infected with chlamydia or gonorrhea should be rescreened 3 months after treatment.
  • Routine screening of asymptomatic adolescents for Trichomonas vaginalis is not recommended, but such screening may be indicated in patients with risk factors such as new or multiple partners, a history of STIs, exchange of sex for payment, or use of injecting drugs.
  • Clinicians should consider rescreening female adolescents and young adults for trichomoniasis 3 months after treatment, or whenever they next present for healthcare in the 12 months after initial treatment.
  • Routine screening of nonpregnant, heterosexual adolescents for syphilis is not recommended.
  • Screening for syphilis is recommended for all sexually active adolescent and young adult MSM annually, or every 3 to 6 months if high risk, based on individual behaviors and local syphilis prevalence.
  • Clinicians should develop clinical procedures using prepared resources to include STI risk evaluation, screening, treatment, and prevention counseling in routine healthcare.
  • Staff should be trained in procedures and related issues, including consent, confidentiality, and billing.
  • Staff should become competent with screening using the noninvasive nucleic acid amplification test (NAAT).
  • Clinicians should advocate for reducing barriers to STI screening, such as access and stigma, without breaching confidentiality.

Clinical Implications

  • An AAP policy statement recommends that sexually active female adolescents and young adults and MSM 25 years or younger be routinely screened annually for chlamydia and gonorrhea. Routine screening for trichomoniasis or syphilis is not recommended.
  • Clinicians should develop clinical procedures using prepared resources to include STI risk evaluation, screening, treatment, and prevention counseling in routine healthcare, according to the AAP.

CME Test

  • Print